• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Matinas Biopharma Holdings Inc.

    6/23/25 5:14:14 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTNB alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on June 23, 2025

     

    Registration No. _______

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

     

    MATINAS BIOPHARMA HOLDINGS, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

    Delaware   46-3011414
    (State or Other Jurisdiction   (I.R.S. Employer Identification No.)
    of Incorporation or Organization)    

     

    1545 Route 206 South, Suite 302

    Bedminster, New Jersey 07921

    (908) 484-8805

    (Address of Principal Executive Offices) (Zip Code)

     

     

    MATINAS BIOPHARMA HOLDINGS, INC. 2025 EQUITY INCENTIVE PLAN

    (Full Title of the Plan)

     

     

    Jerome D. Jabbour

    Chief Executive Officer

    Matinas BioPharma Holdings, Inc.

    1545 Route 206 South, Suite 302

    Bedminster, New Jersey 07921

    (Name and Address Including Zip Code, of Agent for Service)

    (908) 443-1860

    (Telephone Number, Including Area Code, of Agent for Service)

     

     

    With copies to:

     

    Michael J. Lerner, Esq.

    Steven M. Skolnick, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Telephone: (212) 262-6700

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
         
    Non-accelerated filer ☒   Smaller reporting company ☒
       
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    PART I

    Information Required in the Section 10(a) Prospectus

     

    Item 1. Plan Information.

     

    The information called for by Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this “Registration Statement”) and has been or will be sent or given to participating service providers in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

     

    Item 2. Registrant Information and Employee Plan Annual Information.

     

    Matinas BioPharma Holdings, Inc. (the “Company”) will furnish without charge to each person to whom the prospectus is delivered, upon the written or oral request of such person, a copy of any and all of the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II hereof, other than exhibits to such documents (unless such exhibits are specifically incorporated by reference in such documents that are incorporated), and the other documents required to be delivered to eligible participants in the Matinas BioPharma Holdings, Inc. 2025 Equity Incentive Plan pursuant to Rule 428(b) under the Securities Act. Those documents are incorporated by reference in the Section 10(a) prospectus. Requests should be directed to:

     

    Matinas BioPharma Holdings, Inc.

    1545 Route 206 South, Suite 302

    Bedminster, New Jersey 07921

    Attention: Chief Financial Officer

    Telephone: (908) 443-1860

     

    PART II

    Information Required in the Registration Statement

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Company with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

      (a) the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on April 15, 2025;
         
      (b) the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed on May 15, 2025;
         
      (c) the Company’s Current Reports on Form 8-K, filed on January 10, 2025, January 24, 2025, February 7, 2025, February 11, 2025, February 13, 2025, March 11, 2025, March 14, 2025, April 4, 2025, April 8, 2025, May 2, 2025 and June 23, 2025; and
         
      (d) the description of the Company’s common stock contained in our Registration Statement on Form 8-A filed on March 1, 2017, including any amendments and reports filed for the purpose of updating such description, including the description of the common stock included as Exhibit 4.2 to our Annual Report on Form 10-K for the year ended December 31, 2024, filed on April 15, 2025.

     

    All documents filed by the Company pursuant to Section 13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

     
     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    Our Certificate of Incorporation, as amended, and Bylaws provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions of the DGCL, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any amendment by stockholders or directors resolution.

     

    Any repeal or modification of these provisions approved by our stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers existing as of the time of such repeal or modification.

     

    We have director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us, including matters arising under the Securities Act.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    For a list of exhibits, see the Exhibit Index in this Registration Statement, which is incorporated into this Item by reference.

     

     
     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    Provided, however, that Paragraphs (a)(1)(i) and (a)(1)(ii) of this section shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

     
     

     

    EXHIBIT INDEX

     

    Exhibit

    Number

      Description of Exhibit
         
    5.1   Opinion of Lowenstein Sandler LLP.*
    23.1   Consent of EisnerAmper LLP, independent registered public accounting firm.*
    23.2   Consent of Lowenstein Sandler LLP (filed as part of Exhibit 5.1).*
    24.1   Power of Attorney (included on the signature page to this registration statement on Form S-8).*
    99.1   Matinas BioPharma Holdings, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.1. to the Company’s Current Report on Form 8-K filed on June 23, 2025).
    107   Filing Fee Table*

     

    * Filed herewith.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in in the City of Bedminster, State of New Jersey, on June 23, 2025.

     

      Matinas BioPharma Holdings, Inc.
         
      By: /s/ Jerome D. Jabbour
        Jerome D. Jabbour
        Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned officers and directors of Matinas BioPharma Holdings, Inc., a Delaware corporation, do hereby constitute and appoint each of Jerome D. Jabbour and Keith Kucinski as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Jerome D. Jabbour  

    Chairman, Chief Executive Officer & President

    (Principal Executive Officer)

      June 23, 2025
    Jerome D. Jabbour        
             
    /s/ Keith A. Kucinski  

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      June 23, 2025
    Keith A. Kucinski        
             
    /s/ Evelyn D’An   Director   June 23, 2025
    Evelyn D’An        
             
    /s/ Keith Murphy   Director   June 23, 2025
    Keith Murphy        
             
    /s/ Edward Neugeboren   Director   June 23, 2025
    Edward Neugeboren        
             
    /s/ Robin L. Smith   Director   June 23, 2025
    Robin L. Smith        

     

     

     

     

    Get the next $MTNB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MTNB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTNB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Matinas BioPharma downgraded by Piper Sandler

      Piper Sandler downgraded Matinas BioPharma from Overweight to Neutral

      5/11/21 8:00:37 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Murphy Keith

      4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

      5/2/25 5:19:45 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Neugeboren Edward

      4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

      5/2/25 5:19:50 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith Robin L

      4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

      5/2/25 5:19:48 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

      BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of

      2/13/25 5:00:00 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

      BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn

      2/7/25 7:30:00 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Leadership Updates

    Live Leadership Updates

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

      BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of

      2/13/25 5:00:00 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

      BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn

      2/7/25 7:30:00 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Matinas Biopharma Holdings Inc.

      SC 13G - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

      10/25/24 9:15:12 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Matinas Biopharma Holdings Inc. (Amendment)

      SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

      2/14/22 4:43:03 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

      2/16/21 5:01:52 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    SEC Filings

    See more
    • SEC Form S-8 filed by Matinas Biopharma Holdings Inc.

      S-8 - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

      6/23/25 5:14:14 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas Biopharma Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

      6/23/25 4:05:20 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Matinas Biopharma Holdings Inc.

      10-Q - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

      5/15/25 4:42:34 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Financials

    Live finance-specific insights

    See more
    • Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

      BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available o

      8/7/24 7:00:00 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

      BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be available on the IR Ca

      5/2/24 7:00:00 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

      Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today

      3/27/24 4:05:00 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care